XML 29 R19.htm IDEA: XBRL DOCUMENT
v3.21.2

Fair Value Measurements (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2021
Fair Value Disclosures [Abstract] |
Investments Measured at Fair Value on Recurring Basis | Investments at June 30, 2021, which were measured at fair value on a recurring basis, consisted of the following:
|  |  | Fair Value Measurements Using
(in millions) | Fair Value |  | Level 1 |  | Level 2 |  | Level 3
Cash and cash equivalents: |  |  |  |  |  |  |
Cash and money market funds | $ | 368.0 |  |  | $ | 368.0 |  |  | $ | — |  |  | $ | — |
Total cash and cash equivalents | 368.0 |  |  | 368.0 |  |  | — |  |  | — |
Restricted cash: |  |  |  |  |  |  |
Certificates of deposit | 3.2 |  |  | 3.2 |  |  | — |  |  | — |
Total restricted cash | 3.2 |  |  | 3.2 |  |  | — |  |  | — |
Debt securities available-for-sale: |  |  |  |  |  |  |
Commercial paper | 168.6 |  |  | — |  |  | 168.6 |  |  | — |
Corporate debt securities | 442.7 |  |  | — |  |  | 442.7 |  |  | — |
Securities of government-sponsored entities | 243.4 |  |  | — |  |  | 243.4 |  |  | — |
Total debt securities available-for-sale | 854.7 |  |  | — |  |  | 854.7 |  |  | — |
Equity securities: |  |  |  |  |  |  |
Equity securities–biotechnology industry | 38.9 |  |  | — |  |  | — |  |  | 38.9 |
Total equity securities | 38.9 |  |  | — |  |  | — |  |  | 38.9 |
Total recurring fair value measurements | $ | 1,264.8 |  |  | $ | 371.2 |  |  | $ | 854.7 |  |  | $ | 38.9 |
Investments at December 31, 2020, which were measured at fair value on a recurring basis, consisted of the following:
|  |  | Fair Value Measurements Using
(in millions) | Fair Value |  | Level 1 |  | Level 2 |  | Level 3
Cash and cash equivalents: |  |  |  |  |  |  |
Cash and money market funds | $ | 187.1 |  |  | $ | 187.1 |  |  | $ | — |  |  | $ | — |
Total cash and cash equivalents | 187.1 |  |  | 187.1 |  |  | — |  |  | — |
Restricted cash: |  |  |  |  |  |  |
Certificates of deposit | 3.2 |  |  | 3.2 |  |  | — |  | —
Total restricted cash | 3.2 |  |  | 3.2 |  |  | — |  | —
Debt securities available-for-sale: |  |  |  |  |  |  |
Commercial paper | 82.2 |  |  | — |  | 82.2 |  |  | —
Corporate debt securities | 445.9 |  |  | — |  | 445.9 |  |  | —
Securities of government-sponsored entities | 312.9 |  |  | — |  | 312.9 |  |  | —
Total debt securities available-for-sale | 841.0 |  |  | — |  |  | 841.0 |  |  | — |
Equity securities: |  |  |  |  |  |  |
Equity securities–biotechnology industry | 38.2 |  |  | — |  | — |  | 38.2 |
Total equity securities | 38.2 |  |  | — |  | — |  | 38.2 |
Total recurring fair value measurements | $ | 1,069.5 |  |  | $ | 190.3 |  |  | $ | 841.0 |  |  | $ | 38.2 |
Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3) | The following table presents a reconciliation of equity security investments, which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3):
| Three Months Ended June 30, |  | Six Months Ended June 30,
(in millions) | 2021 |  | 2020 |  | 2021 |  | 2020
Balance at beginning of period | $ | 38.9 |  |  | $ | 39.4 |  |  | $ | 38.2 |  |  | $ | 55.9 |
Unrealized gain (loss) included in earnings | — |  |  | 11.3 |  |  | 0.7 |  |  | (5.2) |
Balance at end of period | $ | 38.9 |  |  | $ | 50.7 |  |  | $ | 38.9 |  |  | $ | 50.7 |

X
- Definition Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration